Lyra Therapeutics (formerly known as 480 Biomedical) is a therapeutics company focused on the development of integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It develops LYR-210 and LYR-220, bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis. The company offers XTreo designed to enable sustained delivery of medications for many months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches.